Funding & consortium

iConsensus is funded through the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking and is listed under grant agreement No. 777397. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI2 supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

The consortium is composed of experts in the different technologies from academia and European SME's, as well as EFPIA partners, co-creators of the new technologies of iConsensus and end-users.